Literature DB >> 15250021

Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary.

Tohru Masaoka1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15250021     DOI： 10.1086/383054

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  26 in total

1.  Clinical efficacy and safety of arbekacin for high-risk infections in patients with hematological malignancies.

Authors:  Katsuhiro Miura; Masaru Nakagawa; Hiromichi Takahashi; Yoshihito Uchino; Hitomi Kodaira; Noriyoshi Iriyama; Masashi Sakagami; Shimon Ohtake; Sumiko Kobayashi; Atsuko Hojo; Daisuke Kurita; Yujin Kobayashi; Machiko Kusuda; Yukio Hirabayashi; Yoshihiro Hatta; Masami Takei
Journal:  Int J Hematol       Date:  2015-12-29       Impact factor: 2.490

2.  Role of urine studies in asymptomatic febrile neutropenic patients presenting to the emergency department.

Authors:  Hady Zgheib; Aline El Zakhem; Cynthia Wakil; Mohamad Ali Cheaito; Rola Cheaito; Antoine Finianos; Ralphe Bou Chebl; Rima Kaddoura; Nader Al Souky; Imad El Majzoub
Journal:  World J Emerg Med       Date:  2021

3.  Sepsis in the severely immunocompromised patient.

Authors:  Andre C Kalil; Steven M Opal
Journal:  Curr Infect Dis Rep       Date:  2015-06       Impact factor: 3.725

4.  Optimal timing for pegfilgrastim administration in Japanese breast cancer patients receiving intermediate-risk chemotherapies.

Authors:  Tatsuya Hayama; Kenichi Sakurai; Katsuhiro Miura; Shinsaku Washinosu; Shinya Tsuboi; Akihiro Uchiike; Yoshikazu Yoshida; Masami Takei
Journal:  Int J Clin Pharm       Date:  2018-06-01

5.  Convulsive liability of cefepime and meropenem in normal and corneal kindled mice.

Authors:  Akihiro Tanaka; Kenshi Takechi; Shinichi Watanabe; Mamoru Tanaka; Katsuya Suemaru; Hiroaki Araki
Journal:  Antimicrob Agents Chemother       Date:  2014-05-19       Impact factor: 5.191

6.  Risk factors for febrile neutropenia in neoadjuvant docetaxel, cisplatin, and 5-fluorouracil chemotherapy for esophageal cancer.

Authors:  Hisanaga Nomura; Ken Hatogai; Yosuke Maki; Nobuo Mochizuki; Masaki Tanaka; Shinichiro Saito; Hiroyuki Daiko; Takashi Kojima; Toshikatsu Kawasaki
Journal:  Support Care Cancer       Date:  2019-07-24       Impact factor: 3.603

7.  Incidence and predictors of febrile neutropenia during chemotherapy in patients with head and neck cancer.

Authors:  Yukinori Takenaka; Hironori Cho; Masashi Yamamoto; Susumu Nakahara; Yoshifumi Yamamoto; Hidenori Inohara
Journal:  Support Care Cancer       Date:  2013-06-08       Impact factor: 3.603

8.  Outpatient management without initial assessment for febrile patients undergoing adjuvant chemotherapy for breast cancer.

Authors:  Kosei Kimura; Satoru Tanaka; Mitsuhiko Iwamoto; Hiroya Fujioka; Nayuko Sato; Risa Terasawa; Kanako Kawaguchi; Junna Matsuda; Nodoka Umezaki; Kazuhisa Uchiyama
Journal:  Mol Clin Oncol       Date:  2016-08-12

9.  Diagnostic performance of serum high-sensitivity procalcitonin and serum C-reactive protein tests for detecting bacterial infection in febrile neutropenia.

Authors:  Mizuki Aimoto; Hideo Koh; Takako Katayama; Hiroshi Okamura; Takuro Yoshimura; Shiro Koh; Satoru Nanno; Mitsutaka Nishimoto; Asao Hirose; Mika Nakamae; Takahiko Nakane; Hirohisa Nakamae; Hiroshi Kakeya; Masayuki Hino
Journal:  Infection       Date:  2014-07-20       Impact factor: 3.553

10.  Retrospective study of unplanned hospital admission for metastatic cancer patients visiting the emergency department.

Authors:  Tae Tanaka; Masataka Taguri; Soichi Fumita; Kunio Okamoto; Yoshio Matsuo; Hidetoshi Hayashi
Journal:  Support Care Cancer       Date:  2016-12-13       Impact factor: 3.603
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.